Evidence map›Paper›PMID 28725789›Full record

ArticleAcademic pathology

Improving American Healthcare Through "Clinical Lab 2.0": A Project Santa Fe Report.

James M Crawford, Khosrow Shotorbani, Gaurav Sharma, Michael Crossey, Tarush Kothari, Thomas S Lorey, Jeffrey W Prichard, Myra Wilkerson, Nancy Fisher

Abstract read
In one paragraph

Article in Academic pathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James M CrawfordNorthwell Health Laboratories, Lake Success, NY, USA.
Khosrow ShotorbaniTriCore Laboratories, Albuquerque, NM, USA.
Gaurav SharmaHenry Ford Health Laboratories, Detroit, MI, USA.
Michael CrosseyTriCore Laboratories, Albuquerque, NM, USA.
Tarush KothariNorthwell Health Laboratories, Lake Success, NY, USA.
Thomas S LoreyKaiser-Permanente North Laboratories, Berkeley, CA, USA.
Jeffrey W PrichardGeisinger Medical Center, Danville, PA, USA.
Myra WilkersonGeisinger Medical Center, Danville, PA, USA.
Nancy FisherTriCore Laboratories, Albuquerque, NM, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Project Santa Fe was established both to provide thought leadership and to help develop the evidence base for the valuation of clinical laboratory services in the next era of American healthcare. The participants in Project Santa Fe represent major regional health systems that can operationalize laboratory-driven innovations and test their valuation in diverse regional marketplaces in the United States. We provide recommendations from the inaugural March 2016 meeting of Project Santa Fe. Specifically, in the transition from volume-based to value-based health care, clinical laboratories are called upon to provide programmatic leadership in reducing total cost of care through optimization of time-to-diagnosis and time-to-effective therapeutics, optimization of care coordination, and programmatic support of wellness care, screening, and monitoring. This call to action is more than working with industry stakeholders on the basis of our expertise; it is providing leadership in creating the programs that accomplish these objectives. In so doing, clinical laboratories can be effectors in identifying patients at risk for escalation in care, closing gaps in care, and optimizing outcomes of health care innovation. We also hope that, through such activities, the evidence base will be created for the new value propositions of integrated laboratory networks. In the very simplest sense, this effort to create "Clinical Lab 2.0" will establish the impact of laboratory diagnostics on the full 100% spend in American healthcare, not just the 2.5% spend attributed to in vitro diagnostics. In so doing, our aim is to empower regional and local laboratories to thrive under new models of payment in the next era of American health care delivery.

Indexed as

disruptioninnovationlaboratory medicinepathologyvalue

Identifiers

PMID28725789
PMCPMC5497901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.